Skip to main content
SpringerLink
Log in

Topical Treatment with Glucocorticoids

  • Chapter
Handbook of Atopic Eczema

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 199.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Akers W (1980) Risks of unoccluded topical steroids in clinical trials. Arch Dermatol 116:786–788

    Article  CAS  PubMed  Google Scholar 

  2. Arima Y, Nakai Y, Hayakawa R, Nishino T (2003) Antibacterial effect of beta-thujaplicin on staphylococci isolated from atopic dermatitis: relationship between changes in the number of viable bacterial cells and clinical improvement in an eczematous lesion of atopic dermatitis. J Anti microb Chemother 51:113–122

    CAS  Google Scholar 

  3. Bandmann HJ, Huber-Riffeser G, Woyton A (1966) Kontaktallergie gegen Triamcinolonacetonid. Hautarzt 17:183–185

    CAS  PubMed  Google Scholar 

  4. Bork K (1985) Kutane Arzneimittelnebenwirkungen. Schattauer, Stuttgart

    Google Scholar 

  5. Burckhardt W(1959) Kontakekzem durch Hydrocortison. Hautarzt 10:42–43

    Google Scholar 

  6. Calnan CD (1976) Use and abuse topical steroids. Dermatologica 152[Suppl 1]:247–251

    PubMed  Google Scholar 

  7. Carruthers JA, August PJ, Stoughton RCS (1975) Observations on the systemic effect of topical clobetasol propionate (Dermovate). BMJ 4:203–204

    CAS  PubMed  Google Scholar 

  8. Church R (1969) Sensitivity to hydrocortisone acetate ointment. Br J Dermatol 72:431–444

    Google Scholar 

  9. Cornell RC, Stoughton RB (1985) Topical corticosteroids: guidelines of therapy. Hoechst (Hoechst medication update)

    Google Scholar 

  10. Deffer TA, Goette DK (1987) Distal phalangeal atrophy secondary to topical steroid therapy. Arch Dermatol 123: 571–572

    Article  CAS  PubMed  Google Scholar 

  11. Dooms-Goossens A, Vanhee J, Vanderheyden D, Gevers D, Willems L, Degreef H (1983) Allergic contact dermatitis to topical corticosteroids: clobetasol propionate and clobetasol butyrate. Contact Dermatitis 9:470–478i]

    CAS  PubMed  Google Scholar 

  12. Dooms-Goossens A (1988) Identification of undetected corticosteroid allergy. Contact Dermatitits 18:124–125

    CAS  Google Scholar 

  13. Dooms-Goossens A, Degreef H, Coopmann S (1989) Corticosteroid contact allergy: a reality. In: Frosch PJ, Dooms-Goossens A, Lachapell JM, Rycroft RJG. Scheper RJ (eds) Current topics in contact dermatitis. Springer, Berlin Heidelberg New York, pp 233–237

    Google Scholar 

  14. Du Vivier A, Stoughton RB (1975) Tachyphylaxis to the action of topically applied corticosteroids. Arch Dermatol 111:581–583

    PubMed  Google Scholar 

  15. Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, Bush C, Graeber M (2002) Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 46:495–504

    Article  PubMed  Google Scholar 

  16. Faergemann J, Christensen O, Sjovall P, Johnsson A, Hersle K, Nordin P, Edmar B, Svensson A (2000) An open study of efficacy and safety of long-term treatment with mometasone furoate fatty cream in the treatment of adult patients with atopic dermatitis. J Eur Acad Dermatol Venereol 14: 393–396

    Article  CAS  PubMed  Google Scholar 

  17. Feldman RJ, Maibach HI (1967) Regional variation in percutaneous penetration of cortisol in man. J Invest Dermatol 48:181

    Google Scholar 

  18. Gauger A, Mempel M, Schekatz A, Schafer T, Ring J, Abeck D (2003) Silver-coated textiles reduce Staphylococcus aureus colonization in patients with atopic eczema. Dermatology 207:15–21

    Article  PubMed  Google Scholar 

  19. Gibson JR, Darley C, Kirsch J, Saihan EM, Neild VS (1982) The dilution of proprietary corticosteroid ointments — an attempt to evaluate relative clinical potencies. Br J Dermatol 106:445–447

    CAS  PubMed  Google Scholar 

  20. Gille J (2002) Glukokortikoide. In: Zollner TM, Boehncke WH, Kaufmann R (eds) Atopische Dermatitis. Blackwell Wissenschaftsverlag Berlin, pp 115–125

    Google Scholar 

  21. Gloor M, Hauth A, Gehring W (2003) O/W emulsions compromise the stratum corneum barrier and improve drug penetration. Pharmazie 58:709–715

    CAS  PubMed  Google Scholar 

  22. Gormar FE, Bernd A, Holzmann H (1990) The effect of hydrocortisone aceponate on proliferation, total protein synthesis and collagen synthesis in human skin fibroblasts in vitro. Arzneimittelforschung 40:192–196

    CAS  PubMed  Google Scholar 

  23. Goulding NJ, Flower RJ (2001) Glucocorticoid biology — a molecular maze and clinical challenge. In: Goulding NJ, Flower RJ (eds) Glucocorticoids. Birkhäuser-Verlag Basel

    Google Scholar 

  24. Guy RH, Maibach HI (1985) Calculations of body exposure from percutaneous absorption data. In: Bonaugh RL, Maibach HI (eds) Percutaneous absorption. Dekker, New York, pp 461–466

    Google Scholar 

  25. Hackemüller D (1988) Einfluß von Feuchthaltemitteln auf Hautmodelle und Wirkstoffpenetration in vivo. Thesis, University Düsseldorf, Germany

    Google Scholar 

  26. Haggenmüller F (1993) Irrationale Kortisonangst. Fortschr Med 111:359

    PubMed  Google Scholar 

  27. Hardman JG, Limbird LE, Goodmann, Gilman A (2001) Goodman and Gilman’s the pharmacological basis of therapeutics, 10th edn. McGraw-Hill, New York, pp 1655–1801

    Google Scholar 

  28. Hatz HJ (1998) Glucocorticoide. Immunologische Grundlagen, Pharmakologie und Therapierichtlinien. Medizinisch-pharmakologisches Kompendium. Vol. 12. Wissenschaftliche Verlagsgesellschaft, Stuttgart, pp 603–628

    Google Scholar 

  29. Hausen BM, Kulenkamp D (1985) Kontakallergie auf Fludroxycortid und Cetylalkohol. Dermatosen 33:27–28

    CAS  Google Scholar 

  30. Hausen BM, Foussereau J (1987) The sensitizing capacity of tixocortol pivalate. Contact Dermatitis 17:63–64

    Google Scholar 

  31. Hein R, Korting HC, Mehring T (1994) Differential effect of medium potent nonhalogenated double-ester-type and conventional glucocorticoids on proliferation and chemotaxis of fibroblasts in vitro. Skin Pharmacol 7:300–306

    CAS  PubMed  Google Scholar 

  32. Hench PS, Kendall EC, Slocumb CH, Polley HF (1949) The effect of a hormone of the adrenal cortex 17-hydroxy-11-dehydrocorticosterone (compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin 24:181–197

    CAS  Google Scholar 

  33. Hepburn DJ, Aeling JL, Weston WL (1996) A reappraisal of topical steroid potency. Pediatr Dermatol 13:239–245

    CAS  PubMed  Google Scholar 

  34. Higuchi T (1960) Physical chemical analysis of percutaneous absorption process from creams and ointments. J Soc Cosmet Chem 11:85–97

    Google Scholar 

  35. Kaiser H, Kley HK (2002) Cortisontherapie: Corticoide in Klinik und Praxis, 11th edn. Thieme, Stuttgart

    Google Scholar 

  36. Katz HI, Prawer SE, Watson MJ, Scull TA, Peets EA (1989) Mometasone furoate ointment 0.1% vs. hydrocortisone ointment 1.0% in psoriasis. Atrophogenic potential. Int J Dermatol 28:342–344

    CAS  PubMed  Google Scholar 

  37. Kecskes A, Heger-Mahn D, Kuhlmann RK, Lange L (1993) Comparison of the local and systemic side effects of methylprednisolone aceponate and mometasone furoate applied as ointmentswith equal antiinflammatory activity. J Am Acad Dermatol 29:576–580

    CAS  PubMed  Google Scholar 

  38. Kelly JW, Cains GD, Rallings M, Gilmore SJ (1991) Safety and efficacy of mometasone furoate cream in the treatment of steroid responsive dermatoses. Australas J Dermatol 32:85–91

    CAS  PubMed  Google Scholar 

  39. Kerscher MJ, Korting HC (1992) Topical glucocorticoids of the non-fluorinated double-ester type. Lack of atrophogenicity in normal skin as assessed by high-frequency ultrasound. Acta Derm Venereol 72:214–216

    CAS  PubMed  Google Scholar 

  40. Kerscher MJ, Hart H, Korting HC, Stalleicken D (1995) In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new. Int J Clin Pharmacol Ther 33:187–189

    CAS  PubMed  Google Scholar 

  41. Kooij R (1959) Hypersensitivity to hydrocortisone. Br J Dermatol 71:392–394

    CAS  PubMed  Google Scholar 

  42. Korting HC, Kerscher MJ, Schafer-Korting M (1992) Topical glucocorticoids with improved benefit/risk ratio: do they exist? J Am Acad Dermatol 27:87–92

    CAS  PubMed  Google Scholar 

  43. Korting HC, Vieluf D, Kerscher M (1992) 0.25% Prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream. Eur J Clin Pharmacol 42:159–161

    Article  CAS  PubMed  Google Scholar 

  44. Lepoittevin JP, Drieghe J, Dooms-Goossens A (1995) Studies in patients with corticosteroid contact allergy. Understanding cross-reactivity among different steroids. Arch Dermatol 131:31–37

    Article  CAS  PubMed  Google Scholar 

  45. Lever R, Hadley K, Downey D, McKie R (1988) Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. Br J Dermatol 119:189–198

    CAS  PubMed  Google Scholar 

  46. Lippold BC (1984) Biopharmazie, 2nd edn. Wissenschaftliche Verlagsgesellschaft, Stuttgart

    Google Scholar 

  47. Lippold BC (1984) Selection of the vehicle for topical administration of drugs. Pharm Acta Helv 59:166–171

    CAS  PubMed  Google Scholar 

  48. Lippold BC, Schneemann H (1984) The influence of vehicles on the local bioavailability of betamethasone-17-benzoate from solution and suspension type ointment. Int J Pharm (Amst) 22:31–43

    CAS  Google Scholar 

  49. Maibach HI (1976) In vivo percutaneous penetration of corticoids in man and unresolved problems in their efficacy. Dermatologica 152[Suppl 1]:11–25

    CAS  PubMed  Google Scholar 

  50. Malzfeldt E (1988) KlinischeWirksamkeit von Betamethason-17-benzoat-Salben in Abhängigkeit von der Wirkstofflöslichkeit in der Salbengrundlage. Thesis, University Düsseldorf, Germany

    Google Scholar 

  51. Malzfeldt E, Lehmann P, Goerz G, Lippold BC (1989) Drug solubility in vehicle and efficacy of ointments. Arch Dermatol Res 281:193–197

    Article  CAS  PubMed  Google Scholar 

  52. Maucher OM, Faber M, Knipper H, Kirchner S, Schöpf E (1987) Kortikoidallergie. Hautarzt 38:577–582

    CAS  PubMed  Google Scholar 

  53. McKenzie AW, Stoughton RB (1962) Method for comparing percutaneous absorption of steroids. Arch Dermatol 88:608–611

    Google Scholar 

  54. Meurer M, Folster-Holst R, Wozel G, Weidinger G, Junger M, Brautigam M; CASM-DE-01 Study Group (2002) Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six month study. Dermatology 205:271–277

    Article  CAS  PubMed  Google Scholar 

  55. Meurer M, Wozel G (2003) Behandlung des atopischen Ekzems mit topischen Calcineurininhibitoren. Hautarzt 54:424–431

    CAS  PubMed  Google Scholar 

  56. Niedner R, Ziegenmeyer J (1992) Dermatika: Therapeutischer Einsatz, Pharmakologie und Pharmazie. Wissenschaftliche Verlagsgesellschaft, Stuttgart

    Google Scholar 

  57. Oberdisse E, Hackenthal E, Kuschinsky K (2002) Pharmakologie und Toxikologie, 3rd edn. Springer, Berlin Heidelberg New York

    Google Scholar 

  58. O’Hara JA (1962) Anaphylactic reactions to hydrocortisone injections. BMJ 1:615

    Google Scholar 

  59. Oleffe JA, Blondeel A, de Coninck A (1979) Allergy to chlorocresol and propylene glycol in a steroid cream. Contact Dermatitis 5:53–54

    CAS  PubMed  Google Scholar 

  60. Ostrenga J, Steinmetz C, Poulsen B (1971) Significance of vehicle composition I: relationship between topical vehicle composition, skin penetrability, and clinical efficacy. J Pharm Sci 60:1175–1179

    CAS  PubMed  Google Scholar 

  61. Petro W (1991) Cortisonangst der Patienten. Haut 3:53

    Google Scholar 

  62. Polano MK, Ponec M (1976) Dependence of corticosteroid penetration on the vehicle. Arch Dermatol 112:675–680

    Article  CAS  PubMed  Google Scholar 

  63. Prakash A, Benfield P (1998) Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Drugs 55:145–163

    CAS  PubMed  Google Scholar 

  64. Reitamo S, Lauerma AI, Stubb S, Käyhkö K, Visa K, Förström L (1986) Delayed hypersensitivity to topical corticosteroids. J Am Acad Dermatol 14:582–589

    CAS  PubMed  Google Scholar 

  65. Reitamo S, Rustin M, Ruzicka T (2002) Efficacy and safety of tacrolimus ointment compared with hydrocortisone butyrate ointment in adult patients with atopic dermatitis: the European Tacrolimus Ointment Study Group. J Allergy Clin Immunol 109:547–555

    CAS  PubMed  Google Scholar 

  66. Rote Liste (2004) Editio Cantor Verlag für Medizin und Naturwissenschaften, Aulendorf

    Google Scholar 

  67. Ruzicka T, Assmann T, Homey B (1999) Tacrolimus — the drug for the turn of the century? Arch Dermatol 135:574–580

    Article  CAS  PubMed  Google Scholar 

  68. Schäfer H, Zesch A, Stüttgen G (1982) Skin permeability. Springer, Berlin Heidelberg New York

    Google Scholar 

  69. Schäfer H, Zesch A, Schalla W, Stüttgen G (1984) Pharmakokinetik externer Glucocorticoide. Allergologie 3:194–198

    Google Scholar 

  70. Schäfer-Korting M, Korting HC, Kerscher MJ, Lenhard S (1993) Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids. Clin Pharmacol Ther 54:448–456

    PubMed  Google Scholar 

  71. Schalla W (1985) Lokaltherapiemit Kortikoiden. Z Hautkr 60:609–618

    CAS  PubMed  Google Scholar 

  72. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr (1995) Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 270:283–286

    CAS  PubMed  Google Scholar 

  73. Sears HW, Bailer JW, Yeadon A (1997) Efficacy and safety of hydrocortisone buteprate 0.1% cream in patients with atopic dermatitis. Clin Ther 19:710–719

    Article  CAS  PubMed  Google Scholar 

  74. Sönnichsen N (1962) Beitrag zur Hypercortison-Überempfindlichkeit. Hautarzt 13:226–227

    Google Scholar 

  75. Stierstorfer MB, Baughman RD (1988) Photosensitivity to desoximetasone emollient cream. Arch Dermatol 124: 1870–1871

    Article  CAS  PubMed  Google Scholar 

  76. Stoppoloni G, Prisco F, Santinelli R, Sicuranza C, Giordano C (1983) Potential hazards of topical steroid therapy. Am J Dis Child 137:1130–1131

    CAS  PubMed  Google Scholar 

  77. Stoughton RB (1987) Are generic formulations equivalent to trade name topical glucocorticoids? Arch Dermatol 123:1312–1314

    Article  CAS  PubMed  Google Scholar 

  78. Sulzberger MB, Witten VH (1952) The effect of topically applied compound E in selected dermatoses. J Invest Dermatol 19:101–102

    CAS  PubMed  Google Scholar 

  79. Thaci D (2003) Langzeitmanagement des atopischen Ekzems bei Kindern mit Calcineurininhibitoren. Hautarzt 54:418–423

    CAS  PubMed  Google Scholar 

  80. Tsuij T, Kayoda A, Tanaka R, Kono T, Hamada T (1986) Milia induced by corticosteroids. Arch Dermatol 122:139–140

    Google Scholar 

  81. Vernon HJ, Lane AT, Weston W (1991) Comparison of mometasone furoate 0.1% cream and hydrocortisone 1.0% cream in the treatment of childhood atopic dermatitis. J Am Acad Dermatol 24:603–607

    CAS  PubMed  Google Scholar 

  82. Wachs GN, Maibach HI (1976) Co-operative double-blind trial of an antibiotic corticoid combination in impetiginized atopic dermatitis. Br J Dermatol 95:323–328

    CAS  PubMed  Google Scholar 

  83. Wahn U, Bos JD, Goodfield M et al. (2002) Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 110:e2

    Article  PubMed  Google Scholar 

  84. Watson WS, Findlay AY (1988) The effect of the vehicle formulation on the stratum corneum penetration characteristics of clobetasol-17-propionate in vivo. Br J Dermatol 118:523–530

    CAS  PubMed  Google Scholar 

  85. Wehling M (1994) Non-genomic steroid effects. Trends Endocrinol Metab 5:347

    CAS  Google Scholar 

  86. Wendt H, Frosch PJ (1982) Klinisch-pharmakologische Modelle zur Prüfung von Corticoidexterna. Kerger, Basel

    Google Scholar 

  87. Zaun H, Altmeyer P (1973) Ergebnisse refleksphotometrischer Bestimmungen der Vasoconstriktion nach topischer Steroidapplikation. Arch Dermatol Forsch 247:379–386

    CAS  PubMed  Google Scholar 

  88. Zellweger JP, Andershub HP, Holzer C, Weber H (1994) Welches Image hat das Cortison? Ars Medici 84:231

    Google Scholar 

  89. Zürcher K, Krebs A (1980) Hautnebenwirkungen interner Arzneimittel. Karger, Basel

    Google Scholar 

Download references

Authors
  1. M. Kerscher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Lehmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein, Technische Universität München, Biedersteiner Straße 29, 80802, München, Germany

    Johannes Ring

  2. Klinik und Poliklinik für Dermatologie und Allergologie, Ludwig-Maximilians-Universität, Frauenlobstraße 9-11, 80337, München, Germany

    Bernhard Przybilla

  3. Klinik und Poliklinik für Dermatologie, Heinrich-Heine-Universität, Moorenstraße 5, 40225, Düsseldorf, Germany

    Thomas Ruzicka

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Kerscher, M., Williams, S., Lehmann, P. (2006). Topical Treatment with Glucocorticoids. In: Ring, J., Przybilla, B., Ruzicka, T. (eds) Handbook of Atopic Eczema. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-29856-8_52

Download citation

  • DOI: https://doi.org/10.1007/3-540-29856-8_52

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-23133-2

  • Online ISBN: 978-3-540-29856-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation